The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero
Immunomedics, Inc. (IMMU)

Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other diseases. Co.'s portfolio of investigational products includes antibody-drug conjugates (ADCs), sacituzumab govitecan and labetuzumab govitecan. Co. has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Co. also has other product candidates that target solid tumors and hematologic malignancies created using Co.'s patented DOCK-AND-LOCK® (DNL®) protein conjugation technology. Co. also manufactures and commercializes LeukoScan®.

IMMU SEC Filing Email Alerts Service

Company Name:  Immunomedics, Inc.
Website:  www.immunomedics.com
Sector:  Biotechnology
Number of ETFs Holding IMMU:  25
Total Market Value Held by ETFs:  $98.06M
Total Market Capitalization:  $972.00M
% of Market Cap. Held by ETFs:  10.09%
July 21, 2017    8:47 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Immunomedics, Inc. (IMMU) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2017, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.